Monoclonal Antibody to Fibronectin Leucine Rich Transmembrane Protein 3 (FLRT3)
| Code | Size | Price |
|---|
| MAF453Hu21-20ul | 20ul | £90.00 |
Quantity:
| MAF453Hu21-100ul | 100ul | £169.00 |
Quantity:
| MAF453Hu21-200ul | 200ul | £229.00 |
Quantity:
| MAF453Hu21-1ml | 1ml | £526.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Clonality: Monoclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Immunocytochemistry (ICC)
- Immunohistochemistry (IHC)
- Immunoprecipitation (IP)
- Western Blot (WB)
Further Information
Alternative Names:
Fibronectin-like domain-containing leucine-rich transmembrane protein 3; Leucine-rich repeat transmembrane protein FLRT3
Buffer Formulation:
PBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
Item Name:
Fibronectin Leucine Rich Transmembrane Protein 3
Potency (Clone Number):
C2
Source:
Monoclonal antibody preparation
Usage:
Western blotting: 0.2-2ug/mL;1:500-5000
Immunohistochemistry: 5-20ug/mL;1:50-200
Immunocytochemistry: 5-20ug/mL;1:50-200
Optimal working dilutions must be determined by end user.
Immunohistochemistry: 5-20ug/mL;1:50-200
Immunocytochemistry: 5-20ug/mL;1:50-200
Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Fibronectin Leucine Rich Transmembrane Protein 3 (FLRT3) | RPF453Hu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||